Dendritic cell immunization breaks cytotoxic T lymphocyte tolerance in hepatitis B virus transgenic mice
/in Chronic Virus Hepatitis, International Publications /von 1998-11-01 / J. Immunol. 1998 Nov;161(9):4520-9[Current methods of radiation therapy in patients with prostatic cancer: subtotal body radiation, local hyperthermia]
/in Hyperthermia, International Publications, Prostate Cancer /von 1998-09-01 / Vestn Rentgenol Radiol 1998 Sep-Oct;(5):30-3Pulsing of dendritic cells with cell lysates from either B16 melanoma or MCA-106 fibrosarcoma yields equally effective vaccines against B16 tumors in mice
/in Dendritic Cells, International Publications, Soft Tissue Sarcoma /von 1998-06-01 / J Surg Oncol 1998 Jun;68(2):79-91Induction of primary carcinoembryonic antigen (CEA)-specific cytotoxic T lymphocytes in vitro using human dendritic cells transfected with RNA
/in Colorectal Cancer, Dendritic Cells, International Publications /von 1998-04-01 / Nat. Biotechnol. 1998 Apr;16(4):364-9Extracorporeal whole body hyperthermia treatment of HIV patients, a feasibility study
/in HIV/AIDS, International Publications /von 1997-11-01 / Int J Hyperthermia 1997 Nov-Dec;13(6):577-86Extracorporeal whole body hyperthermia treatments for HIV infection and AIDS
/in HIV/AIDS, International Publications /von 1997-09-01 / ASAIO J. 1997 Sep-Oct;43(5):M830-8Follow-up evaluation of prostate cancer patients infused with autologous dendritic cells pulsed with PSMA peptides
/in Dendritic Cells, International Publications, Prostate Cancer /von 1997-09-01 / Prostate 1997 Sep;32(4):272-8Systemic hyperthermia and ICE chemotherapy for sarcoma patients: rationale and clinical status
/in Hyperthermia, International Publications, Soft Tissue Sarcoma /von 1997-07-01 / Anticancer Res. 1997 Jul-Aug;17(4B):2899-902Tumor-cell number and viability as quality and efficacy parameters of autologous virus-modified cancer vaccines in patients with breast or ovarian cancer
/in Breast Cancer, International Publications, Newcastle Disease Virus, Ovarian Cancer /von 1997-04-01 / J. Clin. Oncol. 1997 Apr;15(4):1354-66IMMUN-ONKOLOGISCHES ZENTRUM KÖLN
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de